Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Table 4 Cost inputs used in the model

Costs	VR-CAP	R-CHOP	Source
Drug costs per treatment cycle	£4,426	£2,383	MIMS 2015 [31], eMIT 2014 [32]
Administration costs first treatment cycle	£1,116	£381	NHS reference costs 2013–2014 [29]
Administration costs per subsequent treatment cycle	£980	£245	NHS reference costs 2013–2014 [29]
Cost per 90 days of second-line treatment & administration	£11,442	£11,665	MIMS 2015 [31], eMIT 2014 [32]
Cost of care at end of life	£6,018	£6,018	Addicott, 2008 [45], Curtis, 2014 [30]

ISSN: 1471-2407